Zobrazeno 1 - 10
of 162
pro vyhledávání: '"Anna, Jonasova"'
Autor:
Anna Jonasova, Slavka Sotakova, Petra Belohlavkova, Lubomir Minarik, Tomas Stopka, Jan Jakub Jonas, Tatiana Aghova, Zuzana Zemanova
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundLuspatercept, an inhibitor of the transforming growth factor beta (TGF-β) pathway, is a novel treatment for anemic patients with lower-risk myelodysplastic syndromes (MDS) with transfusion dependence (TD) who do not respond to erythropoies
Externí odkaz:
https://doaj.org/article/247a1b3de16f41069ac9525bde74c80a
Autor:
Iva Trsova, Andrea Hrustincova, Zdenek Krejcik, David Kundrat, Aleš Holoubek, Karolina Staflova, Lucie Janstova, Sarka Vanikova, Katarina Szikszai, Jiri Klema, Petr Rysavy, Monika Belickova, Monika Kaisrlikova, Jitka Vesela, Jaroslav Cermak, Anna Jonasova, Jiri Dostal, Jan Fric, Jan Musil, Michaela Dostalova Merkerova
Publikováno v:
Molecular Oncology, Vol 17, Iss 12, Pp 2565-2583 (2023)
Mutations in the splicing factor 3b subunit 1 (SF3B1) gene are frequent in myelodysplastic neoplasms (MDS). Because the splicing process is involved in the production of circular RNAs (circRNAs), we investigated the impact of SF3B1 mutations on circR
Externí odkaz:
https://doaj.org/article/cf124e1e1eda474f8d617a5629fc916b
Autor:
Miroslav Pribyl, Sona Hubackova, Alena Moudra, Marketa Vancurova, Helena Polackova, Tomas Stopka, Anna Jonasova, Radka Bokorova, Ota Fuchs, Jan Stritesky, Barbora Salovska, Jiri Bartek, Zdenek Hodny
Publikováno v:
Molecular Oncology, Vol 14, Iss 10, Pp 2403-2419 (2020)
Myelodysplastic syndromes (MDS) are preleukemic disorders characterized by clonal growth of mutant hematopoietic stem and progenitor cells. MDS are associated with proinflammatory signaling, dysregulated immune response, and cell death in the bone ma
Externí odkaz:
https://doaj.org/article/fb9c612ae072482e8ba012c2ca32f842
Autor:
Monika Kaisrlikova, Jitka Vesela, David Kundrat, Hana Votavova, Michaela Dostalova Merkerova, Zdenek Krejcik, Vladimir Divoky, Marek Jedlicka, Jan Fric, Jiri Klema, Dana Mikulenkova, Marketa Stastna Markova, Marie Lauermannova, Jolana Mertova, Jacqueline Soukupova Maaloufova, Anna Jonasova, Jaroslav Cermak, Monika Belickova
Publikováno v:
Leukemia. 36:1898-1906
Patients with lower-risk myelodysplastic syndromes (LR-MDS) have a generally favorable prognosis; however, a small proportion of cases progress rapidly. This study aimed to define molecular biomarkers predictive of LR-MDS progression and to uncover c
Autor:
Michaela Dostalova, Merkerova, Jiri, Klema, David, Kundrat, Katarina, Szikszai, Zdenek, Krejcik, Andrea, Hrustincova, Iva, Trsova, Anh Vu, LE, Jaroslav, Cermak, Anna, Jonasova, Monika, Belickova
Publikováno v:
Cancer Genomics Proteomics
Background/Aim: Prediction of response to azacitidine (AZA) treatment is an important challenge in hematooncology. In addition to protein coding genes (PCGs), AZA efficiency is influenced by various noncoding RNAs (ncRNAs), including long ncRNAs (lnc
Autor:
Andrea Hrustincova, Zdenek Krejcik, David Kundrat, Katarina Szikszai, Monika Belickova, Pavla Pecherkova, Jiri Klema, Jitka Vesela, Monika Hruba, Jaroslav Cermak, Tereza Hrdinova, Matyas Krijt, Jan Valka, Anna Jonasova, Michaela Dostalova Merkerova
Publikováno v:
Cells, Vol 9, Iss 4, p 794 (2020)
Myelodysplastic syndromes (MDS) are hematopoietic stem cell disorders with large heterogeneity at the clinical and molecular levels. As diagnostic procedures shift from bone marrow biopsies towards less invasive techniques, circulating small noncodin
Externí odkaz:
https://doaj.org/article/6694200bbc214c129172b7000b61d9f9
Autor:
Anne Sophie Kubasch, Aristoteles Giagounidis, Georgia Metzgeroth, Anna Jonasova, Regina Herbst, Jose Miguel Torregrosa Diaz, Benoit De Renzis, Katharina S. Götze, Marie-Luise Huetter-Kroenke, Marie-Pierre Gourin, Borhane Slama, Sophie Dimicoli-Salazar, Pascale Cony-Makhoul, Kamel Laribi, Sophie Park, Katja Jersemann, Dorothea Schipp, Klaus H. Metzeler, Oliver Tiebel, Katja Sockel, Silke Gloaguen, Anna Mies, Fatiha Chermat, Christian Thiede, Rosa Sapena, Richard F. Schlenk, Pierre Fenaux, Uwe Platzbecker, Lionel Adès
Publikováno v:
Leukemia.
The EUROPE phase 2 trial investigated the predictive value of biomarkers on the clinical efficacy of single agent romiplostim (ROM) treatment in patients with lower-risk myelodysplastic neoplasms (LR-MDS) and thrombocytopenia within the ‘European M
Autor:
Amanda Fernandes de Oliveira Costa, Miroslava K. Adamcova, Anna Jonasova, Alena Moudra, Meritxell Alberich-Jorda, Robert S. Welner, Hynek Strnad, Izabela Aparecida Lopes, Hong Zhang, Daniel G. Tenen, Sanghoon Lee, Maria Kuzmina, Srdjan Grusanovic, Lorena Lobo de Figueiredo-Pontes, Michal Zidka
Publikováno v:
Stem Cell Reports
Repositório Institucional da USP (Biblioteca Digital da Produção Intelectual)
Universidade de São Paulo (USP)
instacron:USP
Repositório Institucional da USP (Biblioteca Digital da Produção Intelectual)
Universidade de São Paulo (USP)
instacron:USP
Summary Hematopoietic stem cell transplantation (HSCT) is a frequent therapeutic approach to restore hematopoiesis in patients with hematologic diseases. Patients receive a hematopoietic stem cell (HSC)-enriched donor cell infusion also containing im
Publikováno v:
Blood. 140:12311-12312
Autor:
Ota Fuchs, Anna Jonasova, Marketa Vancurova, Jiri Bartek, Radka Bokorova, Sona Hubackova, Zdenek Hodny, Alena Moudra, Tomas Stopka, Barbora Salovska, Jan Stritesky, Helena Polackova, Miroslav Pribyl
Publikováno v:
Molecular Oncology, Vol 14, Iss 10, Pp 2403-2419 (2020)
Molecular Oncology
Molecular Oncology
Aberrantly expressed suprabasin (SBSN) is a novel biomarker in myelodysplastic syndrome (MDS) patients. The highest levels of SBSN, secreted from myeloid subpopulations, including myeloid‐derived suppressor cells, are detectable within bone marrow